Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen phase 3 outcomes trial in cardiovascular disease with elevated lipoprotein(a)
NL-OMON56054Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jun 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity and atherosclerotic disease comparing Pelacarsen with Placebo (2 arms). Primary endpoints: Expanded major adverse cardiovascular events in overall population and Expanded major adverse cardiovascular events in high lipoprotein(a) subgroup. Started Jun 2020; status: recruiting.
02
Drugs
pelacarsen
03
Conditions
cardiac morbidityatherosclerotic disease
Beyond the preview
Go deeper on NL-OMON56054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56054.